NOEMÍ REBOLLO DÍAZ-rekin lankidetzan egindako argitalpenak (8)

2023

  1. Validation and clinical evaluation of an ultra-performance liquid chromatography with ultraviolet detector method for plasma quantification of micafungin

    Annals of Clinical Biochemistry, Vol. 60, Núm. 3, pp. 191-198

2022

  1. Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease

    European Journal of Hospital Pharmacy, Vol. 29, Núm. 4, pp. 222-227

  2. Population pharmacokinetics of a posaconazole tablet formulation in transplant adult allogeneic stem cell recipients

    European Journal of Pharmaceutical Sciences, Vol. 168

2021

  1. Comparison of ultra-performance liquid chromatography and ARK immunoassay for therapeutic drug monitoring of voriconazole

    Annals of Clinical Biochemistry, Vol. 58, Núm. 6, pp. 657-660

2020

  1. A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease

    British Journal of Clinical Pharmacology, Vol. 86, Núm. 6, pp. 1165-1175

  2. Biomarkers of disease activity and other factors as predictors of adalimumab pharmacokinetics in inflammatory bowel disease

    European Journal of Pharmaceutical Sciences, Vol. 150

2019

  1. Therapeutic drug monitoring of tumour necrosis factor inhibitors in the management of chronic inflammatory diseases

    Annals of Clinical Biochemistry, Vol. 56, Núm. 1, pp. 28-41

2011

  1. Modification of the EMIT immunoassay for the measurement of unbound mycophenolic acid in plasma

    Clinical Biochemistry, Vol. 44, Núm. 2-3, pp. 260-263